QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VentriPoint Diagnostics Ltd. (VPTDF) Expands Target Market To Include Pulmonary Hypertension 0 comments
    Jul 8, 2013 2:13 PM | about stocks: VPTDF

    A unique ultrasound-based system for performing right heart analysis, developed by VentriPoint Diagnostics and now used in various hospitals around the world, is also being developed and introduced as a superior approach to diagnose pulmonary hypertension (NYSE:PH), an unhealthy increase in blood pressure in the pulmonary artery or pulmonary vein which can lead to a variety of problems, up to and including heart failure.

    The VentriPoint VMS system, called Angelo, uses 2-dimensional ultrasound data, together with a patented system called Knowledge-Based Reconstruction (NYSE:KBR) for analyzing that ultrasound data. The result is an information-rich 3-dimensional model of the heart. For right heart analysis, it has major advantages over the use of MRI, which is far costlier and time consuming for patients, putting increased pressure on limited hospital resources. Similar advantages apply to the system's use for PH diagnosis. It is already approved in both Europe and Canada and is under review by the FDA. VentriPoint is in discussion with 2D ultrasound OEMs to jointly build a PH-dedicated integrated system,

    As with the system's application to right heart analysis, the ability to use conventional ultrasound equipment, versus more invasive, time consuming and costly procedures, is an underlying advantage to the use of the VentriPoint system for PH diagnosis.

    • PH related drugs work best with early detection, which the VentriPoint system can provide.
    • PH is currently detected using invasive catheterization, an involved and risky procedure.
    • 20 million people are considered at risk for PH, but the number of people actually experiencing the disease is essentially unknown.

    Considering PAH and heart analysis, the remaining market for Angelo's potential use is large. It would take from 2,000 to 5,000 VentriPoint systems to equip all of the hospitals and cardiologist offices in the U.S. The list price of the VentriPoint system is $100,000

    For more information, visit ventripoint.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VPTDF
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.